Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Core Viewpoint - Scilex Holding Company has amended its existing license agreement with Romeg Therapeutics to include ex-US rights for Gloperba®, expanding its commercialization efforts for this innovative anti-gout medication [1][10]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as treatments for neurodegenerative and cardiometabolic diseases through a proposed joint venture with IPMC Company [1][6]. - The company's commercial products include ZTlido®, ELYXYB®, and Gloperba®, with Gloperba® being the first and only liquid oral version of colchicine for gout flare prophylaxis [6][10]. Product Details - Gloperba® is administered orally, with a dosage of 0.6mg per 5ml, providing a solution for patients who have difficulty swallowing pills and allowing for flexible dosing options [2][5]. - Over 70% of gout patients have comorbid conditions that may necessitate dose adjustments, making them a target population for Gloperba® [5]. - The global incidence of gout flares is estimated at 0.1% to 0.3% of the population, with a significant increase in prevalence over the past 30 years, rising from 22 million to 53 million individuals [5]. Market Context - Gout affects between 1% and 6.8% of the population, with rising prevalence attributed to factors such as obesity and comorbidities [3][5]. - Management of gout remains inadequate, with less than half of patients receiving effective urate-lowering therapy, highlighting a significant unmet medical need [3].